Results 111 to 120 of about 5,829,861 (298)

Influence of insulin on growth hormone secretion, level and growth hormone signalling

, 2017
Growth hormone (GH), as a vital hormone, has to experience a series of processes to fulfill its function including secretion, entering the circulation to reach target tissues (pre-receptor process), binding on the GH receptor (GHR) and triggering ...
Qiu, H, Chen, C, Yang, JK
core   +1 more source

RESPONSE OF RECOMBINANT HUMAN GROWTH HORMONE IN ISOLATED GROWTH HORMONE DEFICIENCY

Pakistan Armed Forces Medical Journal, 2007
Objective: To observe the response of growth hormone in isolated growth hormone deficiency. Moreover the response was compared when treatment was initiated earlier or later in childhood. Design: Quasi experimental study.
Shahid Aziz, Salman Ali, Uzair Maqsood, Mehboob Sultan, Shahida Badshah   +4 more
doaj   +2 more sources

Novel mechanisms of growth hormone regulation: growth hormone-releasing peptides and ghrelin

Brazilian Journal of Medical and Biological Research, 2006
Growth hormone secretion is classically modulated by two hypothalamic hormones, growth hormone-releasing hormone and somatostatin. A third pathway was proposed in the last decade, which involves the growth hormone secretagogues.
A.-M.J. Lengyel
doaj   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Early cessation and non-response are important and possibly related problems in growth hormone therapy: An OZGROW analysis

, 2016
Objective: To investigate growth hormone (GH) treatment and treatment cessation with respect to efficacy and efficiency. To identify factors that best classify or predict cessation type: completed treatment (CT), early cessation (EC), or non-response (NR)
Harris, M., Cutfield, W., Cotterill, A, Hughes, IP, Hughes, I., Harris, M, Rath, S, Cutfield, Wayne, Choong, C., Cotterill, A., Rath, S., Choong, C, Hofman, Paul, Atkinson, Helen, Hofman, P., Atkinson, H   +15 more
core   +1 more source

Developments in the Management of Growth Hormone Deficiency: Clinical Utility of Somapacitan

Drug Design, Development and Therapy
Bradley S Miller,1 Jo Blair,2 Reiko Horikawa,3 Agnès Linglart,4– 7 Kevin CJ Yuen8 1Division of Pediatric Endocrinology, University of Minnesota Medical School, MHealth Fairview Masonic Children’s Hospital, Minneapolis, MN, USA; 2Department of Paediatric ...
Miller BS, Blair J, Horikawa R, Linglart A, Yuen KC   +4 more
doaj  

ADP‐ribosylation: An emerging regulator of the epigenome

Molecular Oncology, EarlyView.
ADP‐ribosylation has emerged as a dynamic epigenetic signaling mechanism that modifies histones and chromatin‐associated proteins. Through coordinated PARylation and MARylation, it integrates with other histone modifications to regulate chromatin structure, transcription factor activity, and gene expression, influencing genome function and disease ...
Cristel V. Camacho, Chenqian Liu, W. Lee Kraus   +2 more
wiley   +1 more source

Growth hormone : basic and clinical aspects /

, 1987
Proceedings of the 1st Nordisk insulin symposium Growth hormone: basic and clinical aspects Stockholm, Sweden, 29 June-1 July ...
Nordisk insulin symposium Growth hormone: basic and clinical aspects1st29 June-1 Juli 1987Stockholm, Sweden, Isaksson, Olle,edt   +1 more
core